CGT

774개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved774 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTCurated CoreFDAstaleVertexApproved

exagamglogene autotemcel (Casgevy, exa-cel, CTX001)

Sickle cell disease with recurrent VOCs; transfusion-dependent β-thalassemia · BCL11A enhancer (CRISPR/Cas9) → HbF

#BCL11AenhancerCRISPRCas9HbF#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 9Status Approved
CGTCurated CoreFDAstalebluebird bioApproved

lovotibeglogene autotemcel (Lyfgenia, lovo-cel, bb1111)

Sickle cell disease with recurrent vaso-occlusive events · βA-T87Q-globin (lentiviral)

#A-T87Q-globinlentiviral#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 2Status Approved
CGTLimited DatastaleThomas Martin, MDPhase 1

Chimeric Antigen Receptor T cells (CAR-T, Chimeric Antigen Receptor T cells, Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA)

Multiple Myeloma; Recurrent Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 211Status Discontinued
CGTLimited DatastaleAstraZenecaPhase 2

autologous CD19-directed chimeric antigen receptor (CAR, autologous CD19-directed chimeric antigen receptor, autologous CD19-directed chimeric antigen receptor (CAR) T-cells)

Relapsed Non Hodgkin Lymphoma; Relapsed Adult ALL · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 154Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-B Cell Maturation Antigen (BCMA, Anti-B Cell Maturation Antigen, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells)

Myeloma-Multiple; Myeloma, Plasma-Cell · BCMA

#BCMA#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 131Status Active
CGTLimited DatastaleTcelltech Inc.Phase 1

Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell, Anti-B7-H3 Chimeric Antigen Receptor T-Cell, Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103)

Solid Tumors · B7-H3

#B7-H3#CGT#Phase1#Popular#cell-gene-therapy+4
Trials 92Status Recruiting
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 1

Anti-CD19 CAR T-cells (Anti-CD19 CAR T-cells)

B Cell Malignancies · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 92Status Recruiting
CGTLimited DatastaleShanghai Ming Ju Biotechnology …Phase 2

CD19-targeted Chimeric Antigen Receptor (CAR, CD19-targeted Chimeric Antigen Receptor, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

Lymphoma, Non-Hodgkin; Diffuse Large B Cell Lymphoma · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 64Status Active
CGTLimited DatastaleAbClonPhase 2

Anti-CD19 Chimeric Antigen Receptor T cell (AT101, AT101(Anti-CD19 Chimeric Antigen Receptor T cell))

B-cell Non Hodgkin Lymphoma · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 59Status Recruiting
CGTLimited DatastaleImmunityBio, Inc.Phase 2

Activated NK Cells (M-CENK, M-CENK (Activated NK Cells))

High-risk Prostate Cancer · High-risk Prostate Cancer

#High-riskProstateCancer#CGT#Phase2#Popular#cell-gene-therapy+3
Trials 59Status Discontinued
CGTLimited DatastaleSMT bio Co., Ltd.Phase 2

allogeneic Natural Killer cell ('SMT-NK' Inj, 'SMT-NK' Inj (allogeneic Natural Killer cell))

Biliary Tract Cancer · Biliary Tract Cancer

#BiliaryTractCancer#CGT#Phase2#Popular#cell-gene-therapy+4
Trials 58Status Active
CGTLimited DatastaleCoronado Biosciences, Inc.Phase 2

Allogeneic natural killer cells (Allogeneic natural killer cells)

Leukemia; Lymphoma · Fallopian Tube Cancer

#FallopianTubeCancer#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 58Status Discontinued
CGTLimited DatastaleMedigen Vaccine Biologics Corp.Phase 1

Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell, Recombinant Oncolytic HSV-2 Therapeutic Injecta, Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF))

Melanoma Stage IV · Melanoma Stage IV

#MelanomaStageIV#CGT#Phase1#Popular#cell-gene-therapy+4
Trials 58Status Active
CGTLimited DatastaleMinsk Scientific-Practical Cent…Phase 2

Anti-BCMA CAR-T cells (Anti-BCMA CAR-T cells)

Multiple Myeloma Refractory · BCMA

#BCMA#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 56Status Active
CGTLimited DatastaleNational Taiwan University Hosp…Phase 1

CD19 Chimeric Antigen Receptor (CAR, CD19 Chimeric Antigen Receptor, CD19 Chimeric Antigen Receptor (CAR) T Cells)

Relapsed/Refractory B-Cell Malignancies · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 56Status Active
CGTLimited DatastaleAllife Medical Science and Tech…Phase 2

Cytokine-induced killer cells (Cytokine-induced killer cells)

Ovarian Carcinoma · Cholangiocarcinoma

#Cholangiocarcinoma#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 56Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 2

Anti-cluster of differentiation 19 (CD19, Anti-cluster of differentiation 19, Anti-cluster of differentiation 19 (CD19)-CAR PBL)

Primary Mediastinal B-cell Lymphoma; Diffuse, Large B-cell Lymphoma · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 55Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-cluster of differentiation 19 (CD19, Anti-cluster of differentiation 19, Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells)

Lymphoma, B-Cell; Lymphoma, Non-hodgkins · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 55Status Active
CGTLimited DatastaleYake Biotechnology Ltd.Phase 1

CD19/CD22 CAR T-Cells (CD19/CD22 CAR T-Cells)

Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 54Status Recruiting
CGTLimited DatastaleShenzhen Hornetcorn Bio-technol…Preclinical

CIK cell therapy (CIK cell therapy)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#CGT#Preclinical#Popular#cell-gene-therapy+4
Trials 54Status Active

1 / 39 pages

← PreviousNext →